Ubiquinone and nicotinamide treatment of patients with the 3243A→G mtDNA mutation

Neurology

Volumn 59, Issue 8, 2002, Pages 1275-1277

  Remes, A M ^a   Liimatta, E V ^a   Winqvist, S ^a   Tolonen, U ^b   Ranua, J A ^c   Reinikainen, K ^d   Hassinen, I E ^a   Majamaa, K ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^d ORION CORPORATION   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ATLEVIT; LACTIC ACID; MITOCHONDRIAL DNA; NICOTINAMIDE; PYRUVIC ACID; UBIQUINONE;

ARTICLE; CLINICAL ARTICLE; ELECTROENCEPHALOGRAM; ENCEPHALOMYOPATHY; EVOKED BRAIN STEM AUDITORY RESPONSE; GENE MUTATION; HUMAN; LACTATE BLOOD LEVEL; MITOCHONDRION; NEUROPSYCHOLOGY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037159183     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.8.1275     Document Type: Article

References (10)

1. 10 treatment in mitochondrial encephalomyopathies. Eur Neurol 1997;37:212-218.
2. 10 in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): evaluation by noninvasive tissue oximetry. J Neurol Sci 1999;162:65-68.
3. Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies a multi-center double-blind trial. J Neurol Sci 1990;100:70-78.
4. Matthews PM, Ford B, Dandurand RJ, et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993;43:884-890.
5. Majamaa K, Rusanen H, Remes AM, Pyhtinen J, Hassinen IE. Increase of blood NAD+ and attenuation of lactacidemia during nicotinamide treatment of a patient with the MELAS syndrome. Life Sci 1996;58:691-699.
6. 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavine. Neurology 1992;42:2147-2152.
7. Goto Y, Horai S, Matsuoka T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 1992;42:545-550.
8. Majamaa K, Moilanen JS, Uimonen S, et al. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am J Hum Genet 1998;63:447-454.
9. Katayama K, Takada M, Yuzuhira T, Abe K, Ikenoya S. Simultaneous determination of ubiquinone-10 and ubiquinol-10 in tissues and mitochondria by high pressure liquid chromatography. Biochem Biophys Res Commun 1980;95:971-977.
10. Uimonen S, Moilanen JS, Sorri M, Hassinen IE, Majamaa K. Hearing impairment in patients with 3243A→G mtDNA mutation: phenotype and rate of progression. Hum Genet 2001;108:284-289.